

The University Health Center University of Georgia Athens, GA 30602-1755 706-542-8617 Health Information 706-542-4959 Fax

Name:		
JGA ID#: 81		
Date of Birth:	/_	
hone:		

CERTIFICATE OF IMMUNIZATION (REQUIRED PRIOR TO REGISTERING FOR CLASSES)

(Ok to attach GRITS or other certified immunization record)				
REQUIRED IMMUNIZATIONS	REQUIREMENT (MM/DD/YYYY)	REQUIRED FOR:		
MMR	#1/	All foreign-born students regardless of year born US/Canadian students born in 1957 or later		
(Measles, Mumps, Rubella)	#2 / /	1 st due at 12 months of age or older		
0.5		2 nd dose administered no earlier than 28 days after 1 st		
OR	OR	dose		
Measles (Rubeola)	#1/#2/	US/Canadian students have in 1057 or later		
AND	OR Attached antibody titer (blood test) lab report	US/Canadian students born in 1957 or later If antibody titer does not indicate immunity, injection		
Mumps	#1/#2/ OR Attached antibody titer (blood test) lab report	series required.		
AND	#1/	1 st due at 12 months of age or older		
Rubella (German Measles)	OR Attached antibody titer (blood test) lab report	2 nd dose administered no earlier than 28 days after 1 st dose		
	#1/#2/	<u>SELF/PARENTAL REPORTED HISTORY OF DISEASE</u> NOT A COSPOSED.		
	OR	NOT ACCEPTED All foreign-born students regardless of year born.		
	Attached antibody titer (blood test) lab report			
Varicella (Chicken Pox)	OR	1 st due at 12 months of age or older		
	Definitive diagnosis of varicella by healthcare	2 nd dose administered no earlier than 28 days after 1 st		
	provider. Provide statement from provider	dose • If antibody titer does not indicate immunity, injection		
	verifying previous infection.	If antibody titer does not indicate inimunity, injection		
Tetanus, Diphtheria, Pertussis (Tdap)	Tdap/(REQUIRED)	One dose of Tdap for <i>all</i> students within past 10 years.		
(Tuap)	If unable at home country, obtain at UGA	All Students who will be 18 or younger on the first day of		
Hamataia B	#1/ #2 / /	class.		
Hepatitis B	#2/ #3 / /	If antibody titer does not indicate immunity, injection series required.		
		You <u>must</u> submit the antibody titer report on lab letterhead		
	OR Attached antibody titer (blood test) lab	from a certified lab with definitive lab values in English.		
Tuberculosis (TB)	All students MUST complete the Tuberculosis Screening Questionnaire found on	If the answer to any of the TB screening questions is YES, then must complete the TB Clinical Risk Assessment Part II of		
	healthcenter.uga.edu/info/forms	Form, including TST or IGRA by physician.		
	#1 / /	All newly admitted UGA students living in Campus Housing,		
Meningococcal Vaccine ACWY(MCV4)	#2 / /	or • Sorority or Fraternity Houses.		
Activities 4)		NOTE: A student may sign a statement of understanding in		
(Strongly Recommended for all students <22)	Menactra or Menveo (Please circle one)	lieu of providing proof of immunization.		
		Review meningitis disease information at: healthcenter.uga.edu/healthtopics/meningitis		
Recommended Vaccines:		near the near the proof meaning the		
Meningitis B Vaccine: #1/_	_/#2/ _/ #3/ _/.	(Bexsero/Trumenba) please circle		
Hepatitis A: #1/#2/HPV: #1/#2/ #3/ _/				
Influenza:// COVID: #1/#2// #3// (Pfizer/Moderna/J&J) Please circle				
the University System of Georgia, a I understand I am subject to exclus	affirm that the immunizations required by re in conflict with my religious beliefs sion in the event of an outbreak of disease which imm davit-no older than 6 months signed by student)	Request for Permanent Medical Contraindication (Attach Verification by HealthCare Provider) nunization		
REQUIRED SIGNATURE OF PHYSICIAN O	R HEALTH FACILITY:			
NameAc	ldressPhor	ne Number		
Signature	Date	·		



UNIVERSITY HEALTH CENTER

University of Georgia Athens, GA 30602-1755 Phone: 706-542-1162 Fax Nr: 706-542-4959

or 706-583-0777

NAME:	
UGA ID#:	
Date of Birth: _	

i ait it i abelealosis (i b) selectille questionnali e	Part I: Tuberculosis	(TB) Screening	Questionnaire
--	----------------------	-----	-------------	---------------

Please answer the followin			7D 1' 0		* 7	
•	contact with persons known or	•			Yes	
(If YES, please CIRCLE th	the countries listed below that he country, below) Comoros	Honduras	Mozambique		Yes	□ N
Algeria Angola Anguilla Argentina Armenia Azerbaijan Bangladesh Belize Benin Bhutan Bolivia (Plurinational Stateof) Bosnia and Herzegovina Botswana Brazil Brunei Darussalam Bulgaria Burkina Faso Burundi Cabo Verde Cambodia Cameroon Central African Republic Chad China China, Hong Kong SAR China, Macao SAR	Congo Côte d'Ivoire Democratic People's Republic of Korea Democratic Republic of the Congo Djibouti Dominica Dominican Republic Ecuador El Salvador Equatorial Guinea Eritrea Eswatini Ethiopia Fiji French Polysnesia Gabon Gambia Georgia Ghana Greenland Guatemala Guam Guinea Guinea Guinea Guinea Guinea Guyana Haiti	India Indonesia Iraq Kazakhstan Kenya Kiribati Kuwait Kyrgyzstan Lao People's Democratic Republic Latvia Lesotho Liberia Libya Lithuania Madagascar Malawi Malaysia Maldives Mali Marshall Islands Mauritania Mexico Micronesia (Federated States of) Mongolia Morocco	Myanmar Namibia Nauru Nepal Nicaragua Niger Nigeria Niue Northern Marina Islands Pakistan Palau Panama Papua New Guinea Paraguay Peru Philippines Qatar Republic of Korea Republic of Moldova Romania Russian Federation Rwanda Sao Tome and Principe Senegal Sierra Leone Singapore Solomon Islands Somalia	Sout Sri I Suda Surii Tajik Thai Togo Yoko Tuni Turk Ugan Ukra Uzbo Van Veno Repu Viet Yem Zam	th Sudan Lanka an name kistan iland or-Leste o elau isia kmenistar alu nda aine ted Repul zania guay ekistan uatu ezuela (E ublic of) Nam nen	n blic of 3olivaria
	tion Global Health Observatory, Tuberefer to http://apps.who.int/ghodata.	erculosis Incidence 2012. Count	ries with incidence rates of ≥ 20	cases	per 100,	000
3. Have you had frequent or	prolonged visits to one or mor sease? (If yes, CHECK the cou		pove with a		Yes [☐ No
4. Date last traveled to high	risk country	(state month and ye	ar at least)			
•	and/or employee of high-risk c facilities, and homeless shelter		orrectional		Yes	□ N
6. Have you been a voluntee active TB disease?	er or health-care worker who se	erved clients who are at inc	creased risk for		Yes	□ N
•	mber of any of the following gro or active TB disease – medica				Yes	□ N
	he above questions, University Heal questions is NO, no further testing of		vive TB testing.			
Signature of Student		Date			_	
(Or Signature of <u>Parent</u> if stud Form Reviewed: 3/17; 3/18; 7/21	lent is < 18 yrs. old) Form Revised: 3/16; 5/22	_			-	



UNIVERSITY HEALTH CENTER

University of Georgia Athens, GA 30602-1755 Phone: 706-542-1162

Fax Nr: 706-542-4959 or 706-583-0777

PART II. CLINICAL ASSESSMENT BY HEALTHCARE PROVIDER

are can	ns should review and verify the information in Part I. Persons answering YES to any didates for either Mantoux tuberculin skin test (TST) or Interferon Gamma Release s positive test has been documented.		•	
History	of a positive TB skin test or IGRA blood test? (If yes, document below)		Yes	☐ No
History	of BCG vaccination? (If yes, consider IGRA if possible.)		Yes	☐ No
Do	ymptom Check ¹ bes the student have signs or symptoms of active pulmonary tuberculosis disease? NO, proceed to 2 and 3. If YES, check below:		Yes	□ No
Pr	 □ Cough (especially if lasting for 3 weeks or longer) with or without sputum production □ Coughing up blood (hemoptysis) □ Chest pain □ Loss of appetite □ Unexplained weight loss □ Night sweats □ Fever occeed with additional evaluation to exclude active tuberculosis disease including tubercu 		kin testing, c	hest
2. Tube (T wi	ray (PA and lateral), and sputum evaluation as indicated. Prculin Skin Test(TST) ST result should be recorded as actual millimeters (mm) of induration, transverse diamerite "0". The TST interpretation should be based on mm of induration as well as risk factorite Given: M D Y D Y			ion,
Re	esult:mm of induration **Interpretation: positivenegative			
Da	ate Given:/ Date Read:/			
Re	esult:mm of induration **Interpretation: positivenegative			
<u>≥</u> 5	Interpretation guidelines mm is positive: Recent close contacts of an individual with infectious TB Persons with fibrotic changes on a prior chest x-ray, consistent with past TB disease Organ transplant recipients and other immunosuppressed persons (including receiving equivalent of >15 HIV-infected persons 0 mm is positive: Recent arrivals to the U.S. (<5 years) from high prevalence areas or who resided in one for a significant* injection drug users Mycobacteriology laboratory personnel Residents, employees, or volunteers in high-risk congregate settings	amot	unt of time	
	Persons with medical conditions that increase the risk of progression to TB disease including silicosis, failure, certain types of cancer (leukemias and lymphomas, cancers of the head, neck, or lung), gastred weight loss of at least 10% below ideal body weight.			
>1	5 mm is positive:			

Persons with no known risk factors for TB who, except for certain testing programs required by law or regulation, would otherwise not be tested.



UNIVERSITY HEALTH CENTER

University of Georgia Athens, GA 30602-1755 Phone: 706-542-1162 Fax Nr: 706-542-4959

or 706-583-0777

NAME:	_
UGA ID#:	
Date of Birth:	

Signature:	Date:
Address:	City, State, Zip Code:
Required Signature of Healthcare Provider: Name:	Phone:
Student declines treatment at this time	
Student agrees to receive treatment	
 Populations defined locally as having an increased incidence of dispopulations 	ease due to <i>M. tuberculosis</i> , including medically underserved, low-income
are at increased risk of progression from LTBI to TB dispossible. Infected with HIV Recently infected with <i>M. tuberculosis</i> (within the pHistory of untreated or inadequately treated TB diseconsistent with prior TB disease Receiving immunosuppressive therapy such as tume equivalent to/greater than 15 mg of prednisone per transplantation Diagnosed with silicosis, diabetes mellitus, chronic Have had a gastrectomy or jejunoileal bypass Weigh less than 90% of their ideal body weight Cigarette smokers and persons who abuse drugs and	iate medication. However, students in the following groups ease and should be prioritized to begin treatment as soon as as as 2 years) ase, including persons with fibrotic changes on chest radiograph or necrosis factor-alpha (TNF) antagonists, systemic corticosteroid day, or immunosuppressive drug therapy following organ renal failure, leukemia, or cancer of the head, neck, or lung for alcohol
PART III: MANAGEMENT OF POSITIVE TS	T OR IGRA
4. Chest x-ray: (Required if TST or IGRA is positive. Date of chest x-ray:///Result: normal M D Y	Note: a single PA view is indicated in the absence of sympton abnormal
Result: negative positive indetermination	te borderline(T-Spot only)
Date Obtained: / / / Y (specify met	od) QFT-GIT T-Spot other
Result: negative positive indetermination	te borderline(T-Spot only)
Date Obtained: /// (specify met)	od) QF1-GII I-Spot other
	1) OFFICIE TO (

Form Created: Form Reviewed: 3/17; 3/18; 7/21 Form Revised: 3/2/2016; 5/22